Stefan Berg, general manager of Pharmaplan, one of the leading pharma engineering partners in Europe, outlines the key trends in this area, including an expected investment boom in the coming years as European countries like Switzerland aim to localise their manufacturing and supply chains. Berg explains how Pharmaplan acts as a ‘strategic partner’ to Big Pharma and CDMO clients in Switzerland, providing flexible, GMP-compliant, and future-proof solutions.
General attitudes towards the pharmaceutical industry have shifted, with an increasing realization of the importance of local research and production and an obligation in some geographies to produce antibiotics or vaccines. This could lead to a huge investment wave
